Sarepta Therapeutics: From Exon-Skipping to Gene Therapy – Two Natural Capital
Sarepta Therapeutics' ELEVIDYS gene therapy for Duchenne muscular dystrophy faces critical challenges: controversial FDA approval, $3.2M price tag, limited efficacy, and potential competitive threats from emerging genetic treatments.